ABIVAX Société Anonyme (NASDAQ:ABVX) Sees Large Increase in Short Interest

ABIVAX Société Anonyme (NASDAQ:ABVX) was the recipient of a large growth in short interest during the month of November. As of November 15th, there was short interest totalling 283,200 shares, a growth of 47.6% from the October 31st total of 191,900 shares. Currently, 0.5% of the shares of the company are short sold. Based on an average daily volume of 122,700 shares, the days-to-cover ratio is presently 2.3 days.

ABIVAX Société Anonyme Trading Up 0.7 %

Shares of NASDAQ:ABVX opened at $8.56 on Friday. The stock has a 50 day moving average of $10.11 and a 200 day moving average of $11.80. ABIVAX Société Anonyme has a 12-month low of $8.23 and a 12-month high of $17.02.

Institutional Investors Weigh In On ABIVAX Société Anonyme

Institutional investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets lifted its position in ABIVAX Société Anonyme by 82.6% in the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after buying an additional 5,900 shares during the last quarter. Kennedy Capital Management LLC lifted its position in shares of ABIVAX Société Anonyme by 35.3% during the first quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock worth $1,718,000 after purchasing an additional 31,331 shares during the last quarter. Walleye Capital LLC lifted its position in shares of ABIVAX Société Anonyme by 45.8% during the third quarter. Walleye Capital LLC now owns 257,417 shares of the company’s stock worth $2,965,000 after purchasing an additional 80,807 shares during the last quarter. Point72 Asset Management L.P. lifted its position in shares of ABIVAX Société Anonyme by 28.2% during the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company’s stock worth $6,254,000 after purchasing an additional 119,300 shares during the last quarter. Finally, Janus Henderson Group PLC raised its holdings in shares of ABIVAX Société Anonyme by 18.2% in the first quarter. Janus Henderson Group PLC now owns 851,839 shares of the company’s stock valued at $12,113,000 after acquiring an additional 131,414 shares in the last quarter. 47.91% of the stock is owned by hedge funds and other institutional investors.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.